Role of ivermectin and colchicine in the treatment of COVID-19: a randomized controlled clinical trial

Role of ivermectin and colchicine in the treatment of COVID-19: a randomized controlled clinical trial

 

Hemmat Abd El-Salam Ahmed Salama (1), Eman El-Sayed Ahmed (2), Ghada Essam El-Din Amin, Mohamed Farouk Allam (1), Ahmed Nour El-Din Hassan (3), Mohamed Abd El Rahman Hassan El Shayeb (2)

 

1. Family Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

2. Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

3. Clinical Pharmacology Department, Faculty of Medicine, Galala University, Suez, Egypt.

 

The Journal of Infection in Developing Countries 2024 Dec 31;18(12.1):S298-S304. 

 

DOI: 10.3855/jidc.19862

 

Abstract

Introduction: The objective of this study was to assess the effectiveness of ivermectin and colchicine as treatment options for coronavirus disease 2019 (COVID-19).

Methodology: A three-arm randomized controlled clinical trial was conducted in the Triage Clinic of the family medicine department at Ain Shams University Hospitals on participants who had been diagnosed with moderate COVID-19. Patients aged < 18 years or > 65 years, with any co-morbidities, pregnant or lactating females, and those with mild or severe COVID-19 confirmed cases were excluded. Sealed envelopes were used for randomization of intervention or control. Patients are followed until there was improvement of symptoms and no development of new symptoms for over one month.

Results: A total of 120 patients (40.16 ± 10.74 years) with COVID-19 were enrolled; 40 patients in each arm. Out of them, 44 (36.6%) were male and 76 (63.4%) were female. Fever and cough were the predominant symptoms in each group. There was no statistically significant difference in the mean duration of fever between the ivermectin, colchicine, and control groups (7.3 ± 1.68, 6.6 ± 1.58, and 7.075 ± 1.58 days, respectively). The majority of patients (67.5%, 70%, and 72.5%) were completely cured within 10 days of infection, with no differences between the three groups (p > 0.05). A statistically significant improvement of inflammatory markers occurred in each of the three groups over time with no statistically significant difference between them.

Conclusions: Ivermectin and colchicine have no beneficial effect over standard care in the treatment of COVID-19.

 

Keywords: Ain Shams University; COVID-19; clinical trial; colchicine; ivermectin.

 

Ahmed Salama HAE, Ahmed EE, Amin GEE, Allam MF, Hassan ANE, Hassan El Shayeb MAER. Role of ivermectin and colchicine in the treatment of COVID-19: a randomized controlled clinical trial. J Infect Dev Ctries. 2024 Dec 31;18(12.1):S298-S304. doi: 10.3855/jidc.

 

https://www.jidc.org/index.php/journal/article/view/39863946